Preliminary safety data from a randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.

被引：16
|
作者：
Katz, Matthew H. G.
Varadhachary, Gauri R.
Bauer, Todd W.
Acquavella, Nicolas
Merchant, Nipun B.
Le, Tri Minh
Javle, Milind M.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.4125
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4125
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.
    Rahma, Osama E.
    Katz, Matthew H. G.
    Wolpin, Brian M.
    Dias-Costa, Andressa
    Nowak, Jonathan
    Rodig, Scott J.
    Dougan, Stephanie
    Bekaii-Saab, Tanios S.
    Stucky, Chee-Chee H.
    Elias, Rawad
    Petroni, Gina R.
    Bauer, Todd W.
    Slingluff, Craig L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] RANDOMIZED MULTICENTER STUDY OF NEOADJUVANT CHEMORADIATION THERAPY (CRT) ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RESECTABLE OR BORDERLINE RESECTABLE PANCREATIC CANCER
    Rahma, Osama
    Katz, Mathew
    Bauer, Todd
    Wolpin, Brian
    Stucky, Chee-Chee
    Bekaii-Saab, Tanios
    Elias, Rawad
    Dias-Costa, Andressa
    Nowak, Jonathan
    Patrick, Lenehan
    Petroni, Gina
    Dougan, Stephanie
    Slingluff, Craig
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A1010 - A1010
  • [3] A randomized multicenter phase Ib/II study to assess the safety and the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab (anti-PD1) to CRT alone in patients with resectable or borderline resectable pancreatic cancer.
    Katz, Matthew H. G.
    Bauer, Todd W.
    Varadhachary, Gauri R.
    Petroni, Gina R.
    Bullock, Timothy
    Slingluff, Craig L.
    Rahma, Osama E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] A randomized multicenter phase Ib/II study to assess the safety and the immunological effect of chemoradiation therapy (CRT) in combination with Pembrolizumab (anti-PD1) to CRT alone in patients with resectable or borderline resectable pancreatic canc
    Katz, Matthew H. G.
    Bauer, Todd W.
    Varadhachary, Gauri Rajani
    Adams, Reid B.
    Lankford, Amy R.
    Petroni, Gina
    Bullock, Timothy N.
    Slingluff, Craig L.
    Rahma, Osama E.
    CANCER RESEARCH, 2015, 75
  • [5] Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
    Thanikachalam, Kannan
    Damarla, Vijay
    Seixas, Trevor
    Dobrosotskaya, Irina
    Wollner, Ira
    Kwon, David
    Winters, Kenneth
    Raoufi, Mohammad
    Li, Jia
    Siddiqui, Farzan
    Khan, Gazala
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (06): : 435 - 441
  • [6] Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderline Resectable Pancreatic Cancer
    Suto, Hironobu
    Okano, Keiichi
    Oshima, Minoru
    Ando, Yasuhisa
    Matsukawa, Hiroyuki
    Takahashi, Shigeo
    Shibata, Toru
    Kamada, Hideki
    Kobara, Hideki
    Tsuji, Akihito
    Masaki, Tsutomu
    Suzuki, Yasuyuki
    PANCREAS, 2022, 51 (03) : 269 - 277
  • [7] Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study
    Hiroshi Kurahara
    Hiroyuki Shinchi
    Takao Ohtsuka
    Yoshihiro Miyasaka
    Taketo Matsunaga
    Hirokazu Noshiro
    Tomohiko Adachi
    Susumu Eguchi
    Naoya Imamura
    Atsushi Nanashima
    Kazuhiko Sakamoto
    Hiroaki Nagano
    Masayuki Ohta
    Masafumi Inomata
    Akira Chikamoto
    Hideo Baba
    Yusuke Watanabe
    Kazuyoshi Nishihara
    Masafumi Yasunaga
    Koji Okuda
    Shoji Natsugoe
    Masafumi Nakamura
    Langenbeck's Archives of Surgery, 2019, 404 : 167 - 174
  • [8] Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study
    Kurahara, Hiroshi
    Shinchi, Hiroyuki
    Ohtsuka, Takao
    Miyasaka, Yoshihiro
    Matsunaga, Taketo
    Noshiro, Hirokazu
    Adachi, Tomohiko
    Eguchi, Susumu
    Imamura, Naoya
    Nanashima, Atsushi
    Sakamoto, Kazuhiko
    Nagano, Hiroaki
    Ohta, Masayuki
    Inomata, Masafumi
    Chikamoto, Akira
    Baba, Hideo
    Watanabe, Yusuke
    Nishihara, Kazuyoshi
    Yasunaga, Masafumi
    Okuda, Koji
    Natsugoe, Shoji
    Nakamura, Masafumi
    LANGENBECKS ARCHIVES OF SURGERY, 2019, 404 (02) : 167 - 174
  • [9] Safety of neoadjuvant chemoradiation (CRT) in combination with avelumab (A) in the treatment of resectable esophageal and gastroesophageal junction (E/GEJ) cancer.
    Uboha, Nataliya Volodymyrivna
    Maloney, James D.
    McCarthy, Daniel
    Deming, Dustin A.
    LoConte, Noelle K.
    Matkowskyj, Kristina
    Eickhoff, Jens C.
    Emmerich, Philip
    DeCamp, Malcolm M.
    Lubner, Sam Joseph
    Turk, Anita Ahmed
    Bassetti, Michael Frederick
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Patterns of failure in a phase II trial of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) for resectable and borderline resectable (BLR) pancreatic cancer.
    Kharofa, Jordan
    Mierzwa, Michelle Lynn
    Olowokure, Olugbenga Olanrele
    Sussman, Jeffrey J.
    Latif, Tahir
    Gupta, Anumeha
    Esslinger, Hope
    Poreddy, Sampath
    Mcgill, Brian
    Wolf, Eric
    Smith, Milton T.
    Choe, Kyuran Ann
    Ahmad, Syed A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345